Last Update

2015-02-26T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Scott Pearsall?

Scott Pearsall

Senior Director

ACCELERON PHARMA INC

Direct Phone: (617) ***-**** ext. ***       

Email: s***@***.com

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

ACCELERON PHARMA INC

128 Sidney Street

Cambridge, Massachusetts 02139

United States

Company Description

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the b ... more

Find other employees at this company (172)

Background Information

Education

Ph.D

Web References (13 Total References)


Data presented on September 17, 2006 ...

www.newsrx.com [cached]

Data presented on September 17, 2006 by Scott Pearsall, PhD, director of Preclinical Pharmacology at Acceleron, generated in a mouse model of osteoporosis that showed ACE-011 has positive effects on trabecular and cortical bone, increased bone mineral density and bone strength.


BIO.COM: Biotechnology Pharmaceutical Market, Stocks, Finance, Merger, Acquisition - Biotech, Pharma, Biomedical

www.bio.com [cached]

Data presented on September 17, 2006 by Scott Pearsall, Ph.D., Director of Preclinical Pharmacology at Acceleron, generated in a mouse model of osteoporosis that showed ACE-011 has positive effects on trabecular and cortical bone, increased bone mineral density and bone strength.


Acceleron Pharma

www.acceleronpharma.com [cached]

Data presented on September 17, 2006 by Scott Pearsall, Ph.D., Director of Preclinical Pharmacology at Acceleron, generated in a mouse model of osteoporosis that showed ACE-011 has positive effects on trabecular and cortical bone, increased bone mineral density and bone strength.


Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties

www.acceleronpharma.com [cached]

Data presented on September 17, 2006 by Scott Pearsall, Ph.D., Director of Preclinical Pharmacology at Acceleron, generated in a mouse model of osteoporosis that showed ACE-011 has positive effects on trabecular and cortical bone, increased bone mineral density and bone strength.


Acceleron Pharma ยป Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties

www.acceleronpharma.com [cached]

Data presented on September 17, 2006 by Scott Pearsall, Ph.D., Director of Preclinical Pharmacology at Acceleron, generated in a mouse model of osteoporosis that showed ACE-011 has positive effects on trabecular and cortical bone, increased bone mineral density and bone strength.

Similar Profiles

Other People with this Name

Other people with the name Pearsall

Nels Pearsall
ERS Group Company

Sandy Pearsall
Cardinals

Justin Pearsall
Insight Recruitment Consultants Ltd

Jed Pearsall
Performance Research

Lorraine Pearsall
Historic Takoma , Inc.

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory